Results: A total of 38,040 patients were included (64.9% bovine pericardial; 35.1% porcine). Patient and characteristics were similar between the groups. Median follow-up was 3.6 years. There was no statistically significant difference in survival (P=0.767) (10-year survival was 49.0% and 50.3% in the bovine pericardial and porcine groups respectively) or intervention-free survival. The adjusted hazard ratio for porcine valves was 0.98 . Sensitivity analysis in small valve sizes showed no difference in intervention-free survival. There was some evidence of a protective effect for porcine valves in relatively younger patients (P=0.074).
INTRODUCTION
Biological prosthetic valves are a standard choice of implant for aortic valve replacement (AVR) in older patients, as they do not require the patient to take a lifelong regime of anticoagulation medication, negating the associated complications. There has also been a shift towards biological valve implantation in relatively younger patients reported.
1 Between 2004 and 2008, 21 ,360 out of 30,443 (70.2%) implanted prostheses were reported as being biological. 2 The most frequently implanted biological valves are either porcine xenograft valves or bovine pericardial tissue valves.
These valves have been extensively studied since their first use in the 1960s and 70s because they suffer calcification and structural deterioration, in addition to standard valve replacement complications such as thromboembolic events; endocarditis; and patient-prosthesis mismatch. To date, the evidence base of outcomes for these valves is based on a series of relatively smallrandomised studies and some larger non-randomised case series. The data on comparative outcomes is inconclusive with some reported benefits in haemodynamic and complication endpoints, but no differences in survival. 3 The largest study to date contains fewer than 2000 valves of any one type, which would be unlikely to pick up small but important differences in late outcomes. The aim of this study is to compare the performance of prosthetic porcine xenograft and bovine pericardial valves implanted in aortic valve replacement surgery with respect to in-hospital mortality, mid-term survival and intervention-free survival on a large cohort using 10-years of national registry data collected in hospitals in England and Wales.
MATERIALS AND METHODS

Data extraction and pre-processing
Prospectively collected data were extracted from The National Institute for Cardiovascular
Outcomes Research (NICOR) National Adult Cardiac Surgery Audit (NACSA) registry (version 4.1.2) on 14th January 2014 for all adult cardiac surgery procedures performed in the United Kingdom. As described elsewhere, reproducible cleaning algorithms were applied to the database. 4 Briefly, duplicate records and non-adult cardiac surgery entries (including transcatheter aortic valve 
Statistical analysis
Multiple imputation using chain equations was used to impute missing patient characteristic data and valve size. 5 A total of 5 imputed data sets were generated. Variables included in the imputation models were all clinical and patient study variables in addition to valve model, valve size, year of operation and responsible consultant cardiac surgeon.
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Categorical and dichotomous variables are summarised as absolute number and percentage.
Continuous data are summarised as mean ± standard deviation (SD). Means of continuous variables
were compared between groups using the independent samples t-test. Categorical and dichotomous variables were contrasted using the chi-square test. Due to the large sample size in each valve group, patient characteristics were also compared between bovine pericardial and porcine prostheses by means of standardised (bias) difference. A variable with absolute standardised difference of <10% supports the assumption of 'balance' between the two groups of patients. 6 For each surgeon, the bovine pericardial prosthesis implantation rate is determined and compared to the total case volume.
Time-to-event data are presented as Kaplan-Meier graphs stratified by xenotype, and compared using the log-rank test. To derive adjusted effects for xenotype, for each of the five imputed datasets, a Cox constant proportional hazards models with grouped frailty for the responsible consultant cardiac surgeons was fitted using a Gaussian distribution (with mean zero and standard deviation θ) for the random effects. 7 All extracted patient demographics, comorbidities, and preoperative variables were included in the regression model. Valve type (bovine pericardial / porcine) was forced into the model. The logistic EuroSCORE was not entered into the model as we included most constituent risk factors separately. BMI was included as a quadratic polynomial term. Patient age was entered as piecewise linear polynomial with a single knot at 65 years; this specific modelling decision and knot selection was determined from examination of the smoothed martingale residual plot. 8 The fixed effects for the five models are pooled according to Rubin's rule and reported as hazard ratios with 95% confidence intervals. 9 Two supportive subgroup analyses were performed, each exclusively comparing differences in intervention-free survival. First, we estimated the univariable hazard ratio (taking into account the missing data by multiple imputation and combining the separate results, as per above) for valve type in the subset of patients implanted with a valve of size ≤21mm. Surgeon effects were adjusted for as per above. This is to examine whether any mid-term differences in intervention-free survival are detectable in the spectrum of valve sizes with known gradient differences between bovine pericardial and porcine prostheses. Second, we compared the valve types in patients aged <60 years, and
RESULTS
Exploratory analyses
From a total of 49,375 AVR ± CABG operations with bio-prosthetic implants performed in England and Wales over the 10-year study period, 38,040 patients were included in this study after applying the inclusion and exclusion criteria (Figure 1) . In total 31 different valve classifications were included ( The numbers of missing data were low, with all patient variables having <2% missing data except for BMI (2.5%), pulmonary hypertension (10.1%), creatinine >200 µmol/l (5.4%), haemodynamics (2.8%), active infective endocarditis (6.9%). The patient characteristics between the bovine pericardial and porcine group were well balanced, as shown for the first imputed dataset ( (57.3%) before increasing again (73.2% at 2012-13; Figure 3) . Conversely, the porcine implantation rate forms an n-shape, peaking in 2007-8. Volume has generally been increasing annually.
In-hospital mortality
There were 764 (3.1%) and 406 (3.0%) in-hospital deaths in the bovine pericardial and porcine groups respectively, which was not statistically significantly different (P = 0.806).
Survival
Follow-up data was tracked up until 30th July 2013. A total of 666 patients (1.8% records;
511 bovine pericardial, 155 porcine) did not have post-discharge follow-up; however, they are included in the analysis by censoring them at the point of discharge. The median follow-up time was Survival at 10-years was 49.0% in the bovine pericardial group and 50.3% in the porcine group, however there were only 354 patients (<1%) at risk at this time point.
For regression model development, pulmonary hypertension was removed as it yielded a counterintuitive coefficient and was highly non-significant. NYHA grades I and II were combined into a single reference group for dyspnoea, and stenosis and mixed lesions were combined into a single reference group for haemodynamics. The adjusted hazard ratio for porcine valve implantation was 0.98 [95% CI 0.93 -1.03] (P = 0.41; Table 3 ).
Intervention-free survival
Of the 38,040 first-time cardiac surgery patients who had an AVR ± CABG, 387 (1.0%) had a re-intervention during the follow-up. Of the 387 patients, 376 (97.1%) had a single re-intervention and 11 (2.8%) had two re-interventions. For the composite endpoint of mortality or re-intervention, there were a total of 9002 events during follow-up (5817 bovine pericardial, 3185 porcine), but no statistically significant difference in survival (P = 0.97; Figure 4 ; bottom panel). Intervention-free survival at 1-, 5-and 8-years was 92.0%, 76.4% and 60.2% respectively in the bovine pericardial group, and 91.8%, 76.2% and 60.6% respectively in the porcine group. At 10-years the interventionfree survival was 47.4% and 49.4% in the bovine pericardial and porcine groups respectively. The adjusted hazard ratio for porcine valve implantation was 0.98 [95% CI 0.94 -1.03] (P = 0.50).
Subgroup analyses
Data on valve size was missing in 0.9% (329 / 38,040) of records and were imputed as part of the data imputation algorithm. The mean valve size in the bovine pericardial and porcine groups was There were 2084 patients aged <60 years at time of surgery (68.4% bovine pericardial; 31.6% porcine) and 35,956 patients aged ≥60 years (64.7% bovine pericardial; 35.3% porcine), giving a standardised difference of 3.7%. There was a statistically significant difference in mid-term intervention-free survival when comparing the 4 groups: bovine pericardial <60 years; bovine pericardial ≥60 years; porcine <60 years; and porcine ≥60 years (P < 0.001; Figure 5 ; bottom panel).
Although no difference between valves in the ≥60 years old group (P = 0.87), there was some indication of a protective effect in the porcine valves for the <60 years old group (P = 0.055). It was
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found that in this relatively younger group of patients, the bovine group was on average 1-year older (51.7 vs. 50.6; standardised difference 11.7%); had a higher prevalence of diabetes (13.5% vs. 9.9%; standardised difference 11.2%); and had a higher prevalence of pulmonary hypertension (1.3% vs. survival. 3, 10, 11 There is no difference in survival between valve types in patients with a small prosthesis (≤21 mm), in whom difference in gradient between the valve types would be most marked.
There was some evidence of better long-term intervention-free survival for the porcine valve in the relatively younger patient group (<60 years old), however this did not attain statistical significance.
Comparison to other studies
Reichenspurner et al. examined 1123 bioprostheses (4 bovine pericardial models and 4 porcine models) over a 12-year study window in the aortic (67% of implants), mitral and tricuspid position. 12 They reported a statistically significant (P < 0.05) difference in mid-term survival; at 10- (porcine) implants. 13 They reported survival at 5 years to be 94.4% (bovine pericardial) and 79.6%
(porcine), which was statistically significant (P = 0.039). They postulated that this difference might be attributable to favourable haemodynamics and improved left ventricular hypertrophy regression. This contrasts with our study where we have seen no difference in survival between porcine and bovine pericardial valves at 10-years of follow-up. Our study includes a heterogeneous group of both bovine pericardial and porcine valves, and whilst it does not preclude adverse or indeed superior outcomes in specific model types, it does show the 'class' of tissue valve, per se, does not affect survival.
We found no evidence of selection bias, as measured by the standardised difference.
Therefore, the clinical hypothesis that bovine pericardial valves might be selected for females, who are more likely to have small aortic roots, is not irrefutably supported (standardised difference 5.6%), despite being significantly different (P < 0.001). Interestingly though, this was one of largest standardised differences, with a increase of 2.7 percentage points in female prevalence for bovine pericardial valves. Of interest there was no difference in the incidence of poor left ventricular function between the groups, indicating that surgeons are not in general using this, and the need for better haemodynamics in these patients, as a decision criterion for bovine pericardial valves. After adjusting for other patient characteristics and surgeon effects, choice of valve type was not associated with a difference in survival or intervention-free survival.
Limitations
This study was based on a national registry that has been collected over many years.
Observational 'real world' data routinely has inaccuracies and this registry is no exception. However, there has been extensive validation of the data undertaken after submission and analysis by the units and surgeons submitting data as part of the UK cardiac surgery governance programme. Extensive ongoing data cleaning algorithms were applied to the registry before analysis. Another common limitation of large clinical registries is missing data. The numbers of missing data were relatively small in this study; however a few variables did have a large number of missing data. To overcome this we incorporated multiple imputation, which is a robust method for imputation that also takes into account the additional element of uncertainty.
The National Adult Cardiac Surgery Audit registry does not feature predefined valves for selection in completing valve surgery data. Many hospitals have used a specific coding system or homogenous set of models and some allow free-text by the individual surgeons. This has inevitably led to an increase in data inconsistencies and missing data. A total of 5295 (12.0%) records were excluded due to missing data, unidentified coding, conflicts or unknown xenograft type. This situation is expected to improve in the future due to increased scrutiny on healthcare device monitoring.
Our definition of re-intervention was any surgery on the aortic valve performed up to 31st
March 2013 in a separate subsequent admission spell. A limitation of this is that re-interventions performed between 1st April 2013 and 30th July 2013 (the date of census for mortality tracking) were not included; hence it is possible that the intervention-free survival rates have been slightly underestimated. Re-intervention was determined by identifying patients in the study according to their NHS number who reappeared in the NACSA registry. The NHS number was missing for 1524 patients (4.0%), which required us to track these patients using their patient-hospital number. If these patients have a re-intervention elsewhere, it might not have been properly counted. Finally, a reintervention only included surgical aortic valve procedures. Transcatheter aortic valve implantation has been increasingly used in the United Kingdom in the latter half of this study window; however they are recorded in a separate registry and are therefore not included in the re-intervention rate. 14 We do not believe that any of these limitations could significantly affect the overall findings.
The classification of valves into bovine pericardial and porcine valves masks intra-class variation between models. Numerous studies have compared specific valve types, both within and between xenograft types. [11] [12] [13] 15 Specific valve properties such as stented or stentless mounting might also be associated differently within each xenograft type. 16 The focus of this study is purely on the xenograft type. Although the focus of this study was on xenograft type, future work may involve assessing differences between different valve models.
Although this study recorded results out to a maximum of 10.3 years, the median follow-up time was only 3.6 years. It would be expected that differences would manifest beyond this time interval, thus requiring longer follow-up. Moreover, we do not have data on cause of death, which would be beneficial for learning whether death was due to SVD.
Meaning of study
A number of studies have shown better haemodynamic performance in the bovine pericardial valves than compared to porcine valves. 3, 13, [17] [18] [19] It might be extrapolated that better haemodynamics will translate into more rapid and complete regression of left ventricular modelling with better survival. On the other hand, some studies have shown either superior haemodynamic performance or no-difference in the porcine group compared to the bovine pericardial group. 20, 21 The differential haemodynamics are most marked in small prosthesis size, and as a sensitivity analysis we have repeated our study including only valves with recorded sizes of ≤21 mm and found no change in conclusions. On the basis of these findings there would seem to be clinical equipoise between porcine and bovine pericardial valves. It was previously believed that porcine valves should not be used in younger patients. 22, 23 However, more recent studies have shown that at 20-years, the performance in the Hancock II porcine valve is excellent and superior to that of the Edwards Lifesciences Perimount valve in younger patients. 24, 25 We found that there was a trend towards increased intervention-free survival in the porcine valve group compared to the bovine pericardial group; however, this did not reach statistical significance.
Conclusion
Over 10-years follow-up (with a median follow-up time of 3.6 years), there is no statistically significant difference in the performance of bovine pericardial and porcine bioprostheses implanted into first-time cardiac patients undergoing AVR ± CABG. Follow-up beyond 10-years is required as part of continuous monitoring and other endpoints should be monitored post-operatively including non-surgical re-intervention, functional class and haemodynamics. 3 We have not analysed the data for specific model type within the general bovine pericardial / porcine classes, and it remains possible that specific valve models may be associated with different survival characteristics. 
